ADC Therapeutics lures AbbVie's Zaki to be new CMO

Switzerland-based biotech ADC Therapeutics (NYSE: ADCT) today announced the appointment of Dr Mohamed Zaki as chief medical officer, bringing over 20 years of experience in hematology and oncology drug development to his role.

He will serve on the company’s executive leadership team. Dr Zaki succeeds Dr Joseph Camardo, who is stepping down from full-time work to pursue other avenues to engage with the pharmaceutical industry and patient community.

Dr Zaki joins ADC Therapeutics from AbbVie (NYSE: ABBV), where he most recently served as vice president and global head of oncology development. Prior to AbbVie, he spent nine years at Celgene in increasingly senior roles in oncology and hematology development. Previously, Dr.Zaki worked in clinical development at Sanofi-Aventis and Centocor, a subsidiary of Johnson & Johnson. Dr Zaki also served on the faculty of Ain Shams University School of Medicine in Cairo and the University of Pennsylvania and was a practicing physician earlier in his career.